CAS 951382-34-6|Ipragliflozin L-Proline
| Common Name | Ipragliflozin L-Proline | ||
|---|---|---|---|
| CAS Number | 951382-34-6 | Molecular Weight | 519.58200 |
| Density | / | Boiling Point | / |
| Molecular Formula | C26H30FNO7S | Melting Point | / |
| MSDS | / | Flash Point | / |
Names
| Name | (2S,3R,4R,5S,6R)-2-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-6-(hydroxymethyl)oxane-3,4,5-triol,(2S)-pyrrolidine-2-carboxylic acid |
|---|---|
| Synonym | More Synonyms |
Ipragliflozin L-Proline BiologicalActivity
| Description | Ipragliflozin (L-Proline) is a highly potent and selective SGLT2 inhibitor with an IC50 of 2.8 nM; little and NO potency for SGLT1/3/4/5/6. |
|---|---|
| Related Catalog | Signaling Pathways >>Membrane Transporter/Ion Channel >>SGLTResearch Areas >>Metabolic Disease |
| Target | IC50 value: 2.8 nM (SGLT2)[1][2]. |
| In Vitro | Ipragliflozin (L-Proline) potently and selectively inhibits human, rat, and mouse SGLT2 at nanomolar ranges and exhibits stability against intestinal glucosidases[3]. |
| In Vivo | Ipragliflozin (L-Proline) shows good pharmacokinetic properties following oral dosing, and dose-dependently increases urinary glucose excretion, which lasts for over 12 h in normal mice [3]. Oral administration of ipragliflozin increases urinary glucose excretion in a dose-dependent manner, an effect which is significant at doses of 0.3 mg/kg or higher and lasts over 12 h[4]. Single administration of ipragliflozin dose-dependently increases urinary glucose excretion, reduces blood glucose and plasma insulin levels, and improves glucose intolerance [5]. |
| References | [1]. Imamura M, et al. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. Bioorg Med Chem. 2012 May 15;20(10):3263-79. [2]. Suzuki M, et al. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice. J Pharmacol Exp Ther. 2012 Jun;341(3):692-701. [3]. Tahara A, et al. Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo. Naunyn Schmiedebergs Arch Pharmacol. 2012 Apr;385(4):423-36. [4]. Tahara A, et al. Antidiabetic effects of SGLT2-selective inhibitor ipragliflozin in streptozotocin-nicotinamide-induced mildly diabetic mice. J Pharmacol Sci. 2012;120(1):36-44. [5]. Tahara A, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013 Sep 5;715(1-3):246-55. |
Chemical & Physical Properties
| Molecular Formula | C26H30FNO7S |
|---|---|
| Molecular Weight | 519.58200 |
| Exact Mass | 519.17300 |
| PSA | 167.72000 |
| LogP | 2.29790 |
| InChIKey | TUVGWWULBZIUBS-FVYIYGEMSA-N |
| SMILES | O=C(O)C1CCCN1.OCC1OC(c2ccc(F)c(Cc3cc4ccccc4s3)c2)C(O)C(O)C1O |
| Storage condition | 2-8℃ |
Synonyms
| ASP-1941 |
| Ipragliflozin L-proline |
| UNII-M6N3GK48A4 |
| Ipragliflozin (L-Proline) |
